Published: 26 December 2023
Author(s): Dimitrios Patoulias, Djordje S. Popovic, Theocharis Koufakis, Konstantinos Stavropoulos, Michael Doumas
Issue: March 2024
Section: Letter to the Editor

Tirzepatide is a novel dual gastric inhibitory polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor co-agonist recently approved for the treatment of type 2 diabetes (T2D) and obesity. It represents an acylated peptide designed to activate the GIP and GLP-1 receptors, which are the key mediators of insulin secretion, but are also expressed in regions of the brain that regulate food intake [1]. Tirzepatide reduces plasma glucose and body weight by enhancing β-cell function, delaying gastric emptying, downregulating insulin resistance, increasing satiation, and improving energy expenditure [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.